Supercharging Immunotherapy

More about us

News

HOOKIPA Pharma to Present at Kempen Life Science Conference

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its…

For more information follow the links to our PR and the Poster Presentation
Read More
Poster & Presentation

HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and…

HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results…

Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics …

Publication underscores the potential of our arenavirus platform as a new class of cancer immunotherapeutics.
Read More
Publication

HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life…

The conference is being conducted in a virtual format and a webcast of the presentation will become available on Tuesday, March 09, 2021 at 7:00 AM ET
Read More
all news
fancy black and blue t-cell 3d scientific images immune system

Our Mission

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

read more

Our Pipeline

immuno-oncology
infectious disease
our pipeline

Careers

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

read more